- Home
- FBRX vs IMUX Comparison
FBRX vs IMUX Comparison
Compare FBRX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- IMUX
- Stock Information
- Founded
- FBRX N/A
- IMUX 2016
- Country
- FBRX United States
- IMUX United States
- Employees
- FBRX N/A
- IMUX N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- IMUX Health Care
- Exchange
- FBRX Nasdaq
- IMUX Nasdaq
- Market Cap
- FBRX 84.0M
- IMUX 67.8M
- IPO Year
- FBRX N/A
- IMUX N/A
- Fundamental
- Price
- FBRX $11.80
- IMUX $0.70
- Analyst Decision
- FBRX Strong Buy
- IMUX Strong Buy
- Analyst Count
- FBRX 2
- IMUX 6
- Target Price
- FBRX $61.00
- IMUX $11.60
- AVG Volume (30 Days)
- FBRX 164.2K
- IMUX 2.6M
- Earning Date
- FBRX 08-13-2025
- IMUX 08-07-2025
- Dividend Yield
- FBRX N/A
- IMUX N/A
- EPS Growth
- FBRX N/A
- IMUX N/A
- EPS
- FBRX N/A
- IMUX N/A
- Revenue
- FBRX N/A
- IMUX N/A
- Revenue This Year
- FBRX N/A
- IMUX N/A
- Revenue Next Year
- FBRX N/A
- IMUX N/A
- P/E Ratio
- FBRX N/A
- IMUX N/A
- Revenue Growth
- FBRX N/A
- IMUX N/A
- 52 Week Low
- FBRX $4.11
- IMUX $0.56
- 52 Week High
- FBRX $28.68
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- FBRX 54.37
- IMUX 36.49
- Support Level
- FBRX $10.15
- IMUX $0.68
- Resistance Level
- FBRX $19.63
- IMUX $0.77
- Average True Range (ATR)
- FBRX 1.84
- IMUX 0.07
- MACD
- FBRX -0.22
- IMUX -0.00
- Stochastic Oscillator
- FBRX 22.15
- IMUX 14.09
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.